Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics, Inc. (NASDAQ:VYGR), filed a Form 4 on November 3, 2026, disclosing the acquisition of 33,000 restricted stock units and a stock option covering 154,000 shares of common stock, both granted on November 1, 2026.

Key Highlights

  • RSU award: Carter acquired 33,000 RSUs on November 1, 2026, at a price of $0.00, granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.
  • Stock option grant: A stock option to purchase 154,000 shares of common stock was awarded at an exercise price of $1.72, expiring November 1, 2036.
  • Post-transaction common stock ownership: Carter directly beneficially owns 178,718 shares of common stock following the reported transactions.
  • RSU vesting schedule: The RSU award vests over three years, with 1/3rd vesting on the one-year anniversary of November 1, 2026, and an additional 1/3rd at the end of each successive one-year period, subject to continued service.
  • Option vesting schedule: The stock option vests over four years from a commencement date of October 20, 2026, with 1/48th vesting monthly, subject to continued service.
  • Derivative ownership: Carter directly holds 154,000 derivative securities (stock options) following the reported transaction.

Carter's November 2026 Equity Awards at Voyager Therapeutics

According to the filing, Todd Alfred Carter, serving as Chief Scientific Officer of Voyager Therapeutics, Inc., received two equity awards on November 1, 2026, both issued under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The first is an award of 33,000 RSUs, each representing the right to receive one share of common stock upon vesting. The filing states the vesting commencement date is the grant date, November 1, 2026, with 1/3rd of the underlying shares vesting on the one-year anniversary and an additional 1/3rd at the end of each successive one-year period thereafter, subject to Carter's continued service.

The second award is a stock option granting Carter the right to purchase 154,000 shares of common stock at an exercise price of $1.72 per share, with an expiration date of November 1, 2036, as disclosed in the filing. The vesting commencement date for this option is October 20, 2026. The filing describes the vesting as monthly over four years, with 1/48th of the shares vesting upon the one-month anniversary of the commencement date and an additional 1/48th vesting at the end of each successive one-month period thereafter, contingent on continued service. Both awards were acquired at a reported price of $0.00.

Following the reported transactions, the filing indicates Carter directly and beneficially owns 178,718 shares of common stock and 154,000 stock options. The Form 4 was signed by Todd Alfred Carter and filed on November 3, 2026.

What Was Disclosed

Voyager Therapeutics' Chief Scientific Officer Todd Alfred Carter disclosed the receipt of 33,000 RSUs and a stock option for 154,000 shares at $1.72, both granted November 1, 2026, under the company's 2025 Stock Incentive Plan, resulting in direct beneficial ownership of 178,718 common shares.